Ozempic, or semaglutide, is a medication primarily used for managing type-2 diabetes
As a result, we have seen changes in recommendations for these GLP-1s from second-line to first-line treatment in the ADA Standards of Care in Diabetes 2023 and updates to the ACC 2020 Guidelines for Novel Cardiovascular Risk Reduction in Patients with T2D
Clinical trials have shown promising results, with participants experiencing greater weight reduction compared to those on traditional methods
10.1080/0886022x.2024.2438857 84 TsaiY
| Nasdaq, accessed February 2, 2026, How CDMOs Can Use Patent Data to Win More Pharmaceutical Clients DrugPatentWatch, accessed February 2, 2026, Tirzepatide Ruling: Implications for Compounders in an Evolving Legal Landscape, accessed February 2, 2026,
100